# A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity

> **NIH NIH UG3** · UNIVERSITY OF WASHINGTON · 2022 · $1,791,855

## Abstract

Project Summary
We propose to establish a Hemophilia A Analytical Cohort Research Program (HARP) to support the
development of an Intergenerational Precision Medicine Program for the study of factor VIII (FVIII)
immunogenicity in severe hemophilia A. The first major aim of HARP is to form a new longitudinal
antenatal/neonatal/pediatric severe hemophilia A cohort to study the development of FVIII inhibitors.
The cohort will encompass at least 50 mother-baby pairs, following first genetic carrier mothers and then their
babies with severe hemophilia A over at least the first two years of life. HARP will be responsible for the overall
project coordination, administration, data and biospecimen management, and biostatistics/data analytical
support for the program. The second major aim of HARP is to enable the development of the HARP Shareable
Resource comprised of well annotated data and biological samples collected over the course of the program
accessible through a portal, F8portal.org and a linked biorepository. These resources will be made available to
community researchers. As part of aim 2, protocols will be developed by the HARP Protocols Expert Panel (PEP)
in conjunction with the Consortium of Clinical Centers to support research in four HARP Scientific Emphasis
Areas (SEAs): 1. maternal antenatal research, 2. perinatal research, 3. neonatal/pediatric multi-omics and
immunology research, and 4. hemophilia-event driven neonatal/pediatric multi-omics and immunology research.
The third major aim of HARP is to perform hypothesis-testing research in each of the four Scientific
Emphasis Areas. For the maternal antenatal SEA, we will deeply characterize the mother's expression of FVIII
and the antenatal environment to test our hypothesis that the mother's hemophilia carrier phenotype modulates
inhibitor development by influencing exposure to FVIII tolerizing proteins and future bleeding risk of infant. For
the perinatal SEA, we hypothesize that perinatal exposure to FVIII via expression of F8 gene products are critical
in modulating the FVIII immune response and propose to investigate this via genetic methods in the neonate
and maternal/cord blood. For the neonatal/pediatric -omics and immunology SEA, we hypothesize that
environmental, genetic, and persistent maternal factors promote perturbations in the immune system leading to
a FVIII immune response. We propose to rigorously investigate these factors using genetic, immunologic and -
omics evaluation beginning in neonates and following through early life. Finally, we propose to investigate FVIII
antibody affinity, epitope, and peptide presentation to test our hypothesis that immunologic and/or inflammatory
events occurring around FVIII exposure influence production of FVIII-IgG1 and ultimately inhibitors for the
hemophilia event-driven SEA. Together, this proposal seeks to provide rigorous scientific and clinical data
with biospecimens and expert support for a communal resource to drive innovative i...

## Key facts

- **NIH application ID:** 10512711
- **Project number:** 1UG3HL165064-01
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Jill Marie Johnsen
- **Activity code:** UG3 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,791,855
- **Award type:** 1
- **Project period:** 2022-09-21 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10512711

## Citation

> US National Institutes of Health, RePORTER application 10512711, A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity (1UG3HL165064-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10512711. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*